PROKIDNEY CORP (PROK) Stock Price & Overview
NASDAQ:PROK • US74291D1046
Current stock price
The current stock price of PROK is 1.985 USD. Today PROK is down by -4.57%. In the past month the price decreased by -1.42%. In the past year, price increased by 116.62%.
PROK Key Statistics
- Market Cap
- 597.148M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.55
- Dividend Yield
- N/A
PROK Stock Performance
PROK Stock Chart
PROK Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PROK. When comparing the yearly performance of all stocks, PROK is one of the better performing stocks in the market, outperforming 93.14% of all stocks.
PROK Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PROK. PROK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PROK Earnings
On March 13, 2026 PROK reported an EPS of -0.12 and a revenue of 217.00K. The company beat EPS expectations (10.87% surprise).
PROK Forecast & Estimates
15 analysts have analysed PROK and the average price target is 6.63 USD. This implies a price increase of 234.01% is expected in the next year compared to the current price of 1.985.
PROK Groups
Sector & Classification
PROK Financial Highlights
Over the last trailing twelve months PROK reported a non-GAAP Earnings per Share(EPS) of -0.55.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.2% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PROK Ownership
PROK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.99 | 368.381B | ||
| AMGN | AMGEN INC | 15.42 | 189.472B | ||
| GILD | GILEAD SCIENCES INC | 15.93 | 175.4B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.26 | 114.717B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.59 | 78.668B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.05 | 41.749B | ||
| INSM | INSMED INC | N/A | 30.759B | ||
| NTRA | NATERA INC | N/A | 28.033B | ||
| BIIB | BIOGEN INC | 11.34 | 26.756B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.73 | 23.245B | ||
| MRNA | MODERNA INC | N/A | 20.695B | ||
| EXAS | EXACT SCIENCES CORP | 341.64 | 19.805B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.443B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PROK
Company Profile
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
Company Info
IPO: 2021-06-30
PROKIDNEY CORP
2000 Frontis Plaza Blvd, Suite 250
Winston-Salem NORTH CAROLINA US
Employees: 204
Phone: 13369997028
PROKIDNEY CORP / PROK FAQ
What does PROKIDNEY CORP do?
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
What is the stock price of PROKIDNEY CORP today?
The current stock price of PROK is 1.985 USD. The price decreased by -4.57% in the last trading session.
Does PROK stock pay dividends?
PROK does not pay a dividend.
What is the ChartMill rating of PROKIDNEY CORP stock?
PROK has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for PROKIDNEY CORP?
PROKIDNEY CORP (PROK) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for PROKIDNEY CORP?
PROKIDNEY CORP (PROK) has a market capitalization of 597.15M USD. This makes PROK a Small Cap stock.